Tag Archive for: Phase 1b data

Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration

/in

Phase Ib/IIa study found VES001, the first oral therapy being tested in FTD, led to >95% mean increase in progranulin levels in CSF, compared to baseline Topline results indicate VES001 normalises levels of progranulin in people who have a shortage of this vital protein for genetic reasons, potentially stopping them developing symptomatic frontotemporal dementia (FTD) […]

Read more

Rejuvenate Biomed announces positive results from Phase 1b clinical trial with RJx-01 in sarcopenia

/in

Diepenbeek, Belgium, October 4, 2023 – Rejuvenate Biomed NV (“Rejuvenate Biomed”), a clinical-stage company dedicated to advancing therapeutics to delay the onset of age-related diseases, today announced the successful completion of a 6-week clinical proof-of-mechanism study with lead candidate RJx-01. RJx-01, a novel combination drug comprising galantamine and metformin, demonstrated positive results in 42 elderly male subjects […]

Read more